We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

23 hedge funds and large institutions have $31.4M invested in Theriva Biologics in 2013 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

100% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 3

53% more funds holding

Funds holding: 15 → 23 (+8)

35% more capital invested

Capital invested by funds: $23.3M → $31.4M (+$8.13M)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
23
Holders Change
+8
Holders Change %
+53.33%
% of All Funds
0.67%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.06%
New
8
Increased
6
Reduced
3
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TS
Third Security
Virginia
+$3.61M
2
KCM
Knoll Capital Management
Florida
+$1.96M
3
MP
MSD Partners
New York
+$833K
4
RA
Royce & Associates
New York
+$505K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$404K

Top Sellers

Rank Fund Capital Flow
1
BCM
Bridgeway Capital Management
Texas
-$50.5K
2
Janney Montgomery Scott
Janney Montgomery Scott
Pennsylvania
-$50.5K
3
Morgan Stanley
Morgan Stanley
New York
-$25.2K
4
Creative Planning
Creative Planning
Kansas
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
TS
1
Third Security
Virginia
$18.8M +$3.61M +286 +26%
MP
2
MSD Partners
New York
$4.09M +$833K +66 +28%
KCM
3
Knoll Capital Management
Florida
$2.05M +$1.96M +155 New
BGA
4
Belmont Global Advisors
Texas
$1.92M +$1.8M +143 New
RA
5
Royce & Associates
New York
$1.19M +$505K +40 +82%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.17M +$404K +32 +57%
Janney Montgomery Scott
7
Janney Montgomery Scott
Pennsylvania
$410K -$50.5K -4 -11%
Bank of America
8
Bank of America
North Carolina
$356K – – –
DCM
9
DAFNA Capital Management
California
$283K +$265K +21 New
LMF
10
LMR Master Fund
Cayman Islands
$202K +$189K +15 New
California Public Employees Retirement System
11
California Public Employees Retirement System
California
$157K – – –
Geode Capital Management
12
Geode Capital Management
Massachusetts
$150K – – –
LOM
13
Loeb Offshore Management
New York
$122K +$114K +9 New
BFA
14
BlackRock Fund Advisors
California
$101K +$12.6K +1 +14%
Northern Trust
15
Northern Trust
Illinois
$69K +$12.6K +1 +25%
BCM
16
Bridgeway Capital Management
Texas
$61K -$50.5K -4 -44%
WTNA
17
Wilmington Trust National Association
Delaware
$56K – – –
Goldman Sachs
18
Goldman Sachs
New York
$50K +$50.5K +4 New
Morgan Stanley
19
Morgan Stanley
New York
$41K -$25.2K -2 -40%
HLA
20
Hamilton Lane Advisors
Pennsylvania
$36K – – –
TDC
21
Thompson Davis & Co
Virginia
$31K +$25.2K +2 New
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$22K – – –
GC
23
Guggenheim Capital
Illinois
$16K +$12.6K +1 New
GT
24
Glenmede Trust
Pennsylvania
$3K – – –
Citigroup
25
Citigroup
New York
$2K – – –
1
2

TOVX Hedge Fund Activity: Q4 2013 in Review

23 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q4 2013, worth a combined $31.4M — up 35% from $23.3M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TOVX positions and 0 closed out — a net gain of 8 holders — while 6 added to existing stakes and 3 trimmed.

The largest buyer was Third Security, adding an estimated $3.61M. The largest seller was Bridgeway Capital Management, cutting an estimated $50.5K.

  • 23 institutional investors held Theriva Biologics (TOVX) as of Q4 2013, up from 15 in Q3 2013.
  • Funds reported $31.4M of Theriva Biologics stock for Q4 2013, up 35% quarter-over-quarter.
  • 8 funds opened new Theriva Biologics positions in Q4 2013 and 0 closed out, a net change of +8 holders.
  • The largest Theriva Biologics buyer in Q4 2013 was Third Security, an estimated $3.61M added.
  • The largest Theriva Biologics seller in Q4 2013 was Bridgeway Capital Management, an estimated $50.5K sold.

Based on aggregated 13F filings for Q4 2013.